Skip to main content
. Author manuscript; available in PMC: 2017 Feb 1.
Published in final edited form as: Mol Cancer Res. 2015 Nov 18;14(2):207–215. doi: 10.1158/1541-7786.MCR-15-0321

Figure 5.

Figure 5

(A) Immunoblot of MEK1 and β-ACTIN (loading control) protein levels from pooled population of cells 5 days after lentiviral infection of Cas9 with control sgRNA targeting GFP or two independent sgRNAs targeting MAP2K1 in RKO and SNU-C1 cells.

(B) Cell viability beginning 7 days after Cas9/sgRNA infections. Viability is normalized to mock infected controls for each cell line.

(C) Trametinib dose response curve after 6 days. Cell viability normalized to DMSO treated controls. The dashed line approximately represents the serum concentration achieved from the recommended dose determined from Phase I clinical trials (25).

(D) Immunoblot of MEK1 and β-ACTIN (loading control) protein levels from pooled population of cells 5 days after lentiviral infection of Cas9 with control sgRNA targeting GFP or two independent sgRNAs targeting MAP2K1 in AGS and OCUM-1 cells.

(E) Cell viability beginning 7 days after Cas9/sgRNA infections. Viability is normalized to mock infected controls for each cell line.

(F) Trametinib dose response curve after 6 days. Cell viability normalized to DMSO treated controls. The dashed line approximately represents the serum concentration achieved from the recommended dose determined from Phase I clinical trials (25).